[Endoscopic treatment of bleeding ulcers: has everything been said and done?].
Endoscopic treatment reduces bleeding recurrence, the need for surgery and mortality in patients with bleeding ulcers. However endoscopic treatment fails in 10-15% of patients, leading to high morbidity and mortality. The therapeutic measures with demonstrated effectiveness in reducing the risk of hemorrhagic recurrence and its complications are combined endoscopic treatment (adrenaline plus a second hemostatic intervention) and proton pump inhibitors. Also useful, although there is less evidence, are immediate resuscitation and <<second look>> endoscopy. Some studies suggest that activated recombinant factor VII infusion or supra-selective arterial embolization can be useful in severe hemorrhage. Further studies are required to determine optimal treatment according to the characteristics of each patient.
Unitat de Malalties Digestives, Hospital de Sabadell, Institut Universitari Parc Taulí, Universitat Autònoma de Barcelona, Sabadell, Barcelona, España. xcalvet@cspt.es
X
X
Calvet
M
M
Vergara
E
E
Brullet
D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D019090:Case Management; D015331:Cohort Studies; D003131:Combined Modality Therapy; D004384:Duodenoscopy; D004837:Epinephrine / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005167:Factor VII / Q000627:therapeutic use; D015942:Factor VIIa; D005544:Forecasting; D005773:Gastroscopy; D006801:Humans; D015201:Meta-Analysis as Topic; D010438:Peptic Ulcer Hemorrhage / Q000188:drug therapy / Q000601:surgery*; D054328:Proton Pump Inhibitors; D011994:Recombinant Proteins / Q000627:therapeutic use; D012008:Recurrence; D012151:Resuscitation; D024162:Second-Look Surgery
D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa; D004837:Epinephrine